Key Points Eli Lilly's high valuation could limit the stock's future returns. Viking Therapeutics is a much smaller company, and it has a promising GLP-1 asset in VK2735. Encouraging data around VK2735 recently gave the stock a big boost. 10 stocks we like better than Viking Therapeutics › Investing in a top company can offer safety and stability, but oftentimes, the potential upside can also be limited. Take Eli Lilly (NYSE:LLY) as a prime example. It's a leader in the GLP-1 space and a top healthcare company, with a market cap of more than $1 trillion. It's generated impressive returns totaling more than 400% in five years, but with a much higher valuation, it may not perform nearly as well over the next five years.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.